BRIEF—Gilead opens new pediatric facility in Dublin

US biotech major Gilead Sciences has announced the formal opening of an office focused on developing new pediatric formulations for its portfolio of medicines in Dublin, Ireland.

Development, clinical operations, legal/IP, medical affairs and regulatory teams will work together to create the company’s only Global Pediatric Center of Excellence.

Daniel O’Day, chairman and chief executive, Gilead Sciences, said: “Gilead's therapies address some of the world's most challenging viral diseases, including HIV, viral hepatitis and COVID-19.

“Our Dublin teams play a critical role in adapting these therapies to treat children. In addition, as Gilead expands its work in oncology, our Irish teams could help to address the urgent challenge of childhood cancers.”

The Dublin Development office is responsible for coordinating pediatric trials for seven products across 18 countries, with current trials investigating pediatric treatments for HIV, hepatitis B and COVID-19.

Gilead plans to expand the responsibilities of the Dublin operations further, including supporting work on adult studies across its portfolio of approved and investigational medicines. A new team will also be recruited in the Dublin office to form a core part of a new Artificial Intelligence Center within the Gilead Development organization.